Ivacaftor+lumacaftor ( DrugBank: Ivacaftor, Lumacaftor )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 299 | Cystic fibrosis | 1 |
299. Cystic fibrosis
Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03475381 (ClinicalTrials.gov) | January 22, 2016 | 4/1/2018 | Real-life Follow-up of Cystic Fibrosis Patients Treated With Ivacaftor+Lumacaftor (Orkambi*) | Real-life Follow-up of Cystic Fibrosis Patients Treated With Ivacaftor+Lumacaftor (Orkambi*) | Cystic Fibrosis | Drug: Ivacaftor+lumacaftor | Assistance Publique - Hôpitaux de Paris | Effi-Stat;Societe Francaise de la Mucoviscidose | Completed | 12 Years | N/A | All | 852 | France |